Scientific Programme

28 August 2019   29 August 2019  30 August 2019  31 August 2019  1 September 2019


SEE other Pre-Conference workshops & sessions

Wednesday, 28 August 2019

Special Session: Latest Research from China (pre-conference)


Special Session WELCOME

Opening remarks by Dr Liang Xiao Feng


Part 1: Animal and Zoonotic Influenza in China 

9:15 - 9:45

9:45 - 10:15

10:15 - 10:45

10:45 - 11:15

Avian Influenza Control in China - Hualan Chen | Chinese Academy of Agricultural Sciences

Human Infections with Zoonotic Influenza Virus in China - Dayan Wang | Chinese National Influenza Centre, People's Republic of China

Human Infections with Novel Influenza Viruses and Pandemic Preparedness in China - Lei Zhou | Public Health Emergency Centre, China CDC

Seasonal Influenza Vaccine Policy Development and Implementation in China - Luzhao Feng | Division of Infectious Diseases, China CDC

11:15 - 11:30

Refreshment Break


Part 2: Pharmaceutical Research in China (with a focus on Chinese Medicine)

11:30 - 12:00


12:00 - 12:30

12:30 - 13:00

Adjuvant Use of Traditional Chinese Medicine in Influenza and Pneumonia - Bin Cao | China-Japan Friendship Hospital, People's Republic of China

Repression of Antiviral Genes Stat1 and 2 in Avian Influenza Infection - Chengyu Jiang | Chinese Academy of Medical Sciences, People's Republic of China

Prediction of Zoonotic Influenza Virus Transmission and Clinical Severity Using Biomarkers - Yuelong Shu | School of Public Health,Sun Yat-Sen University, People's Republic of China


End of Special Session: Latest Research from China


15:00 - 15:30


Lance Jennings, ISIRV Chair

Vernon Lee, OPTIONS X Chair

Dr Lam Pin Min, Senior Minister of State for Health and Transport

15:30 - 16:00

Coffee Break in the Exhibit Hall

16:00 - 17:30

Opening Keynotes

Pandemic/Avian Flu Through the Years/Risk to the Future - Malik Peiris (University of Hong Kong)

A Bird's Eye View of Influenza Research - Kanta Subbarao (Peter Doherty Institute for Infection and Immunity, Australia)

Impact of Influenza/Pandemics - What Can be Done for the Future? - Mike Ryan (WHO, Switzerland)

17:30 - 18:30 Welcome Reception (Main Hall 406 CX)

18:30 - 19:30 Poster session 1- Clinical Sciences & Co-infection (Exhibit Hall)


Thursday, 29 August 2019

8:30 - 10:00

Plenary Session 1 - Vaccines

Challenges in Influenza Prevention and Control - Dan Jernigan [CDC, Atlanta, USA]

Design Options for Universal Influenza Vaccines - Barney Graham [NIAID, USA]

10:00 - 10:30 Coffee Break in the Exhibit Hall

10:30 - 12:00


Virus Pathogenesis & Transmission Clinical I Vaccine Efficacy / Effectiveness I

1. Influenza Transmission in Experimental and Field Settings - Hui-Ling Yen (University of Hong Kong)                        

1. Rapid Diagnosis of Influenza - Maria Zambon (Public Health England) 1. Do Influenza Vaccines Attenuate the Severity of Breakthrough Infections? - Mark Thompson (CDC, USA)

2. Pathogenesis and Transmission of Emerging Influenza Viruses - Sander Herfst [Erasmus MC, Netherlands]

2 Shifting the Diagnostic Paradigm from Pathogen to Host - Ann Falsey (University of Rochester, USA)

2. Impact on cardiovascular outcomes - Jeff Kwong (ICES, Canada)

3. Implications of Incomplete Viral Genomes for Influenza A Virus Fitness - Anice Lowen (Emory University, Atlanta, US)

3.Innovation in Pandemic Influenza Response - Rick Bright (US Dept. of Health and Human Services, USA)

Abstract No 10311: variations in seasonal influenza vaccine effectiveness due to biological characteristics: A systematic review and META-analysis of test-Negative design studies - George Okoli (University of Manitoba, Canada)

Abstract No 10440: Autophagy-mediated restriction of avian influenza virus replication in mammalian cell - Siwen LIU (The University of Hong Kong, Hong Kong)

Abstract No 10563: The impact of syndromic molecular point-of-care testing for respiratory viruses in adults presenting to hospital with exacerbation of airways disease: further analysis form a randomised controlled trial - Nathan Brendish (University Hospital Southampton NHS Foundation Trust, UK)

Abstract No 10395: Vaccine effectiveness against influenza hospitalization in the 2018-2019 season: comparison between cell-based and egg-based influenza vaccines – Hung Fu Tseng (Kasier Permanente Southern California, USA)

Abstract No 10855: Haemagglutinin mutation and higher neuraminidase activity enhanced the adaption of H5N6 avian influenza viruses to mammalian hosts - Honglei Sun (China Agricultural University, People’s Republic of China)

Abstract No 10565: Evaluation of the Febridx host response point-of-care test to differentiate viral from bacterial aetiology in adults hospitalised with acute respiratory illness during influenza season - Nathan Brendish (University Hospital Southampton NHS Foundation Trust, UK)

Abstract No 10881: Influenza vaccine effectiveness against laboratory-confirmed influenza mortality in older adults – Jeff Kwong (ICES, Canada)

Abstract No 10945: Assessment of zoonotic transmission of swine influenza a viruses from pigs to naïve or vaccinated ferrets - Ian Brown [Animal and Plant Health Agency, UK]  

Abstract No 10499: Relative vaccine effectiveness of high dose versus adjuvanted influenza vaccine: a retrospective cohort study - Robertus van Aalst  (Sanofi Pasteur, USA)

12:00 - 14:30

12:00 - 13:30



Lunch Break in Exhibit Hall 

Sponsored Lunch Symposium - Sanofi Pasteur            Hall 406CX

Beyond Acute Respiratory Disease: How to Demonstrate the Full Public Health Impact of Influenza and its Prevention

13:30 - 14:30 ISIRV Annual General Meeting

14:30 - 16:00


Clinical II Vaccine Efficacy/Effectiveness II Co-infection
1 Neuraminidase Inhibitors: In Pursuit of Laboratory Correlates of Clinically Relevant Resistance- Larisa Gubareva (CDC, USA) 1 Explaining Differences in Vaccine Effectiveness and Virus Circulation in the Southern Hemisphere, 2019 - Sheena Sullivan (WHO Collaborating Centre for Reference and Research on Influenza, Australia) 1 The Potential of Vaccines to Address Antimicrobial Resistance - Padmini Srikantiah (Bill & Melinda Gates Foundation, USA)
2 Antiviral resistance [Polymerase Inhibitors] - Aeron Hurt (Peter Doherty Institute, Australia) 2 Immune Responses to Repeated Vaccination - Annette Fox (Doherty Institute, Australia) 2 Bacterial Interactions: The Role of Influenza in the Epidemiology of Pneumonia - Pej Rohani (University of Georgia, USA)
3 Clinical Studies on Immunopathogenesis - Jake Dunning (Public Health England, UK) 3 Variable Effects of annually repeated inflenza vaccination:evidence, mechanisms and implications - Danuta Skowronski (CDC, British Columbia, Canada) 3 Management of Co-infection in Emerging Influenza - Insights from the WHO New Standard Influenza Clinical Management Guidance - Nahoko Shindo (WHO, Switzerland)

Abstract No 10877: Rapid molecular testing for influenza in children improves patient management in acute care setting – Rangaraj Selvarangan (Childrens MercyHospital, USA)

Abstract No 11047: Birth cohort-specific vaccine effectiveness against influenza A(H1N1)PDM09 in seasons with different A(H1N1)PDM09 virus vaccine components, I-move multicentre primary care study, Europe, 2013/14 TO 2018/19 - Esther Kissling (Epiconcept, France) Abstract No 10912: Epidemiology of influenza-associated community-acquired pneumonia admissions: A 7-year retrospective cohort study in Singapore - Win Mar Kyaw (TTSH, SG)

Abstract No 10750: Seasonal and other influenza viruses with reduced susceptibility to Baloxavir and Pimodivir  - Larisa Gubareva (CDC, USA)

Abstract No 10983: Viral genomic variation and vaccine effectiveness across consecutive influenza A(H3N2) epidemics in Canada, 2016-17 and 2017-18 - Danuta Skowronski (British Columbia Centre for Disease Control, Canada)

Abstract No 10904: Evaluating the window of susceptibility to secondary bacterial infections post-influenza infection in ferrets - Edin Mifsud (Peter Doherty Institute, Australia)

16:00 - 16:30 Coffee Break in the Exhibit Hall

16:30 - 18:00


Influenza Glycobiology Clinical III Surveillance & Forecasting
1 Evolution of Virus-Glycan Interactions - Andrew Thompson (Scripps Research Institute, USA) 1 Inhibiting Viral Polymerase in Treating Influenza: Clinical Updates - Nelson Lee (University of Alberta, Canada)

1 Forecasting Seasonal Influenza Activity - Jeff Shaman (Columbia University, USA)

2 N-Glycolylneuraminic Acid as a Receptor for Influenza A Viruses - Rob de Vries (Utrecht Institute for Pharmaceutical Sciences, NL) 2 Polyclonal and Monoclonal Antibodies for the Treatment of Influenza - John Beigel (NIAID, USA) 2 Building a Forecasting Capability for Australian Public Health - Rob Moss (The University of Melbourne, Australia)
3 Defining Correlates of Immunity Against Influenza Using Systems Serology - Galit Alter (Ragon Institute of MGH, MIT and Harvard, USA) 3 Management of Antiviral Resistance: Lessons from the Transplant Population - Mike Ison (Northwestern University, USA) 3 Forecasting Virus Strains - Trevor Bedford (Fred Hutchinson Cancer Research Center, USA]

Abstract No 11089: Influenza a virus surface proteins are organized to help penetrate host mucus – Michael Vahey (Washington University in St. Louis, USA)

Abstract No 10753: Emergence of viruses with reduced susceptibility to Baloxavir Marboxil: Impact on clinical and virologic outcomes in patients with influenza at high risk of complications (Capstone-2) - Simon Portsmouth [Shionogi Inc., USA] Abstract No 11184: Globalization complicated emergence and spread of H3N2 seasonal influenza A viruses - Xiu-Feng (Henry) Wan (University of Missouri-Columbia, USA)

Abstract No 10964: Seasonal H1N1 and antigenically drifted H3N2 influenza viruses that have limited binding to sialic acid bind to phosphorylated high mannose glycans from the human lung - Lauren Byrd-Leotis (Harvard Medical School, USA)

Abstract No 10900: Neuraminidase-targeted hapten immunotherapy to treat influenza -  Xin Liu (Purdue University, USA)

Abstract No 10347: FluSight: Six seasons of forecasting influenza in the United States, 2013–14 to 2018–19 - Matthew Biggerstaff (CDC, USA)

18:00 - 19:30

Sponsored Evening Symposium - Hoffman-Roche

Can we stop flu going viral?

18:00 - 20:00

ISIRV Epidemiology Group Session


Friday, 30 August 2019

8:30 - 10:00

Plenary Session 2: PISA & Virology

Combination Influenza Therapy: Concept to Clinical Reality - Fred Hayden (University of Virginia School of Medicine)

Challenges in Influenza - Yoshi Kawaoka (University of Wisconsin-Madison, USA and University of Tokyo, Japan)

10:00 -10:30 Coffee Break in the Exhibit Hall

10:30 - 12:30


NextGen/Universal Vaccines Clinical IV Optimising Vaccine Strategies I

1 The Influenza Virus Neuraminidase as a Vaccine Target - Florian Krammer (Icahn School of Medicine USA)

1 Adjuvant Therapy for Severe Influenza Infection - Ivan Hung (University of Hong Kong)

1 Strategies to Enhance Local Protective Influenza-Specific Immunity in the Respiratory Tract - Andrea Sant (University of Rochester Medical Center, USA)

2 Next-Generation Broadly Reactive Influenza Vaccines - Ted Ross (University of Georgia, USA) 2 Adjuvant Use of Corticostroids in Influenza and Pneumonia - Bin Cao (China-Japan Friendship Hospital, People's Republic of China) 2 Comparitive Immunogenicity of Enhanced Influenza Vaccines in Older Adults in Hong Kong: A Randomized Controlled Trial (PIVOT) - Ben Cowling (University of Hong Kong)
3 T cell Vaccines Against Influenza - Sarah Gilbert (University of Oxford, UK) 3 Potential Host-targeted Therapies in Influenza - Andres Pizzorno (CIRI, France) Abstract No 10390: Serologic response to sequential influenza vaccination in older adults from a randomized trial -Huong McLean (Marshfield Clinic Research Institute, USA)

Abstract No 11170: Characterising human memory B cells with cross-lineage recognition of the influenza B hemagglutinin following seasonal immmunisation - Adam Wheatley (University of Melbourne, Australia)

Abstract No 11025: Development of a new class of broad spectrum influenza PB2 inhibitors - Sam Lee (Cocrystal Pharma Inc., USA) Abstract No 11171: Prior infection enhances the magnitude and breadth of anti-H3N2 antibody responses to influenza vaccination and reduces the risk of subsequent A/H3N2 virus infection -Maria Auladell (Peter Doherty Institute for Infection and Immunity, Australia)

Abstract No 11110: Intranasal M2SR (M2-deficient single replication) influenza vaccine induced protection against challenge with a substantially drifted H3N2 virus in a phase 2 study - Joseph Eiden (FluGen, USA)

Abstract No 11127: Intravenous Peramivir in emergency department high-risk patients with influenza: A multicenter randomized controlled study - Yu-Hsiang Hsieh (Johns Hopkins University School of Medicine , USA) Abstract No 10609: Does strain change influence vaccine effectiveness against influenza A (H3N2)? - Huong McLean (Marshfield Clinic Research Institute, USA)

Abstract No 10535: A human broadly cross-reactive anti-neuraminidase antibody protects against different subtypes of influenza A and B viruses in the mouse model - Daniel Stadlbauer (Icahn School of Medicine at Mount Sinai, USA)

Abstract No 10475: Human-to-human transmission of influenza A(H3N2) viruses exhibiting reduced susceptibility to Baloxavir due to a PA I38T substitution in Japan – Emi Takashita (National Institute of Infectious Diseases, Japan)

Abstract No 10561: Repeat vaccination reduces antibody affinity maturation irrespective of influenza vaccine platform in humans - Surender Khurana (Center for Biologics Evaluation and Research (CBER), FDA, USA)

Abstract No 10880: Pre-existing immunity to the conserved hemagglutinin stalk of influenza virus may drive selection for an escape mutant virus in humans - Jae-Keun Park (National Institute of Health, USA)

Abstract No 11286: Pharmacokinetics of Favipiravir (T-705) in combination with Oseltamivir for treatment of critically ill patients with severe influenza - Yeming Wang (Institute of Respiratory Medicine, Chinese Academy of Medical Science, People’s Republic of China) Abstract No 10385: Comparison of influenza antibody titers among women who were vaccinated in the 2nd and 3rd trimesters of pregnancies - Joshua A. Mott (U.S.CDC, Thailand)

Abstract No 10980: RNACTIVE©: A promising mRNA based influenza vaccine - Lidia Oostvogels (CureVacAG, Germany)

Abstract No 11217: A Randomized controlled trial on the effect of fever suppression by antipyretics on influenza -  Dennis Kai Ming Ip (The University of Hong Kong, Hong Kong) Abstract No 10375: Heterologous prime-boost using AS03 adjuvanted A(H5N1) pandemic stockpiled influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost - Min Levine (CDC, USA)

12:30 - 14:00

12:30 - 14:00

Lunch Break in Exhibit Hall

Sponsored Lunch Symposium - Seqirus

Raising Defenses: Strengthening Influenza Protection

14:00 - 16:00


Immune Response to Infection Special Populations - Clinical Aspects Optimising Vaccine Strategies II

1 Human CD8+ T cell cross-reactivity across Influenza A,B and C Viruses - Katherine Kedzierska (University of Melbourne, Australia)

1.Impact of Influenza Vaccination During Pregnancy on the Mother, Fetus and Infant - Marta Nunes (University of Witwatersrand, South Africa)

1 Efficacy of Live-attenuated Vaccines - Martin Friede (WHO, Switzerland)

2 How the Host Response Determines Disease Outcome After Influenza Virus Infection - Paul Thomas (St Jude Children's Research Hospital, USA) 2 Influenza and Older Adults: Frailty, Function and Healthy Ageing - Melissa Andrew (Dalhousie University and Canadian Centre for Vaccinology, Canada) 2. Influenza Vaccination of Children - What Have We Learnt? - Richard Pebody (Public Health England, UK)
3 The Pandemic Matrix Gene Enhances Innate Responses During Infection -  Mark Tompkins (University of Georgia, USA) 3. Influenza in Children: Challenges and Unanswered Questions- Andrew Pavia (University of Utah, USA) Abstract No 10811: The United Kingdom’s childhood influenza vaccination programme: Review of uptake and vaccine effectiveness over the first six seasons - George Kassianos (Royal College of General Practitioners, UK)

Abstract No 10528: Annotation and recovery of ferret-specific immunoglobulin sequences - Julius Wong (University of Melbourne, Australia)

Abstract No 11345: Lower cognition among toddlers who experience acute respiratory illnesses in Panama and El Salvador - Eduardo Azziz-Baumgartner (CDC , USA) Abstract No 11195: Impact of the introduction of the paediatric live attenuated influenza vaccine (LAIV) programme: An intercountry comparison across the United Kingdom and the Republic of Ireland - Mary Anissa Sinnathamby (Public Health England, UK)

Abstract No 10490: Broadened cross-reactive immunity in ferrets after repeated influenza A/H3 exposures - Hang Xie (Center for Biologics Evaluation and Research, US Food and Drug Administration, USA)

Abstract No 11300: Long-Term Care/Nursing Home admission following hospitalization with influenza and acute respiratory illness: The role of social vulnerability. A report from the Canadian Serious Outcomes Surveillance Network. -  Melissa K Andrew (Dalhousie University, Canada) Abstract No 10913: First trimester seasonal influenza vaccination and major congenital malformations: A 2010-2016 UK retrospective cohort study - Punam Mangtani (London School of Hygiene and Tropical Medicine, UK)

Abstract No 10471: Molecular and functional dissection of the influenza virus-specific CD8+ T-Cell receptor repertoire during aging - Carolien van de Sandt  (The University of Melbourne at The Peter Doherty Institute, Australia)

Abstract No 10712: Effect of treatment with neuraminidase inhibitors on the risk of in-hospital death among influenza patients reported from EU countries, 2010–2019 -  Cornelia Adlhoch (ECDC, Sweden) Abstract No 10749: Viral shedding in recipients of live attenuated influenza vaccine in the 2016/17 and 2017/18 influenza seasons in the United Kingdom - David Jackson (Public Health England, UK)

Abstract No 11035: Innate-like signatures of influenza-specific CD8+ resident memory T cell responses in the human lung - Suzanna Paterson (Imperial College, UK)

Abstract No 11163: Impact of antiviral therapy on short- and long-term outcomes of patients with Copd following influenza infection -  Christopher Wallick (Genentech, USA) Abstract No 10376: Cost-effective analysis for influenza vaccination coverage and timing in tropical and subtropical climate settings: a modelling study - Mu Yue (NUS, SG)

Abstract No 11216: Subdominance and diminished tfh elicitation constrain humoral immunity against the influenza Ha-stem - Hyon-Xhi Tan (Peter Doherty Institute for Infection and Immunity at the University of Melbourne, Australia)

Abstract No 11161: Treating influenza with antivirals is associated with a decreased burden of complications and health resource utilization in high risk patients -  Christopher Wallick (Genentech, USA)

Abstract No 10332: Costs and effects of childhood influenza vaccination in the Netherlands: important risk of undesirable effects - Pieter de Boer (National Institute for Public Health and the Environment, Netherlands)

16:00 - 16:30 Coffee Break in the Exhibit Hall

16:30 - 18:00


Cellular and Molecular Virology Avian and Zoonotic Influenza Infection Severity

1 Next Generation Orally Efficacious Influenza Drug Candidate with High Genetic Resistance Barrier - Richard Plemper (Georgia State University, USA)

1 Lessons and Experience of Clinical Diagnosis and Treatment on Avian Influenza Cases in Guangzhou, China - Zhong Nan Shan (Guangzhou Medical University, People's Republic of China)

1 Pandemic Severity Assessment - Carrie Reed (CDC, USA)

2 Structural Snapshots of Actively Transcribing Influenza Polymerase - Stephan Cusack  (European Molecular Biology Laboratory in Grenoble, France) 2 Zoonotic Transmissions of Influenza A Viruses at Agricultural Fairs - Andrew S Bowman (Ohio State University, USA) 2 Disease Severity in Influenza and Other Respiratory Viral Infections - Barbara Rath (Vienna VaccineSafety Initiative, Germany/USA)
3 The Interplay Between Influenza and Cellular Sphingolipids - Hassan Zaraket (American University Beirut, Lebanon) 3 Clinical Features of Influenza A(H5N1) Infection and other NA subtypes - David Hui (The Chinese University of Hong Kong) 3 The FLU CATs Study - Validation of Triage Tools for Use Across a National Healthcare System During Surge in Healthcare Demand Due to Pandemic Influenza - Calum Semple (University of Liverpool, UK)

Abstract No 11313: Dissecting the mechanism of signaling-induced nuclear export of influenza virus vRNPs - Stephan Ludwig (University of Muenster, Germany)

Abstract No 10853: Incidence and seroprevalence of avian influenza viruses among Egyptian backyard poultry growers: Results from a prospective cohort study - Ghazi Kayali (Human Link,  Lebanon) Abstract No 11254: Burden and severity of influenza-like illness in Australia: 10 years of flutracking online surveillance - Craig Dalton (University of Newcastle, Australia)

Abstract No 10698: Differential regulation of Post-Translational Modification (PTM) status of influenza A viral Ribonucleoproteins (RNPs) during different stages of the viral life cycle - Lin Zhu (Hong Kong Baptist University, Hong Kong)

Abstract No 10966: Clinical evaluation of adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic A(H7N9) influenza virus  -  Ruben O. Donis (BARDA, USA) Abstract No 10547: Estimating the influenza disease pyramid in Singapore - Rachael Pung (MOH, SG)

18:00 - 19:30

Poster Session 2 - Virology & Pathogenesis (Exhibit Hall)


Saturday, 31 August 2019

8:30 -10:00

Plenary Session 3 - WHO Vision and Approaches

Global Influenza Strategy: Where We Want To Be In a Decade - Ann Moen (WHO, Switzerland)

Pandemic Influenza Preparedness - 10 Years After Pandemic H1N1 2009 - Wenqing Zhang (WHO, Switzerland)

Measuring Influenza Severity: Where We Are and Where We Will Go - Katelijn Vandemaele (WHO, Switzerland)

10:00 -10:30 Coffee Break in the Exhibit Hall
10:30 - 12:30


Host-Pathogen Interactions Influenza in the Tropics Policy Perspectives for the Prevention and Control of Seasonal Influenza

1 Immunity to Influenza in Dirty Mice - Ryan Langlios (University of Minnesota, USA)

1 Influenza in the Tropics - Lance Jennings (University of Otago, NZ)

1 Effectiveness of Influenza Vaccination in Different Populations - Brendan Flannery (CDC, USA)

2 Obesity as a risk factor in influenza virus infection - Stacey Schultz-Cherry [St Jude Children's Research Hospital, USA] 2 'Seasonality' of Influenza in the Tropics Due to Waning of Protection - Alex Cook (NUS, SG) 2 Rational Policy for Neuraminidase Inhibitors - Jonathan Nguyen Van Tam (Dept. of Health and Social Care, UK)
3 ANP32 Proteins:Host Factors That Impact Influenza Virus Polymerase Activity and Host Range - Wendy Barclay [Imperial College London, UK] 3 Monitoring Influenza Activity and Burden in the Tropics - Mark Chen (NUS, SG)

3 Policy considerations for the Prevention and Control of Seasonal Influenza - Kong Insik (Ministry of Health and Welfare, Republic of Korea)

Abstract No 10428: Spatial and temporal quantification of putative lung regenerating cells during early recovery from influenza pneumonia- Joe Ong (NUS, SG)

Abstract No 11211: Resistance development in influenza a viruses infecting mallards exposed to low levels of Peramivir - Josef Järhult (Uppsala University, Sweden) 4 Evidence Needed to Accelerate Influenza Vaccine Introduction into National Immunisation Programme in China - Hongjie Yu (Fudan University, People's Republic of China)

Abstract No 11138: Obesity increases the cardiac complications of influenza virus infection - Kirsty Short (University of Queensland, Australia)


Abstract No 10100: Live attenuated influenza vaccine induces early tonsillar follicular t helper cell responses correlating with durable systemic antibody responses - Sarah Larteley Lartey Jalloh (University of Bergen, Norway)

5 Panel discussion on overcoming challenges for implementation of prevention and control of seasonal influenza -

Kong Insik (Ministry of Health and Welfare, Republic of Korea)

Hongjie Yu (Fudan University, People's Republic of China)

Seng Heng (Ministry of Health, Cambodia)

Chong Chee Kheong (Ministry of Health, Malaysia)


Abstract No 11112: A history of obesity reduces the immune response to influenza virus in an NLRP3 dependent manner - Katina D. Hulme (University of Queensland, Australia)

Abstract No 11289: Development of a universal Influenza A T cell-based vaccine - Elizabeth Eagling-Vose (Vaccitech, UK)

Abstract No 10740: Repeated seasonal influenza vaccination results in reduced protection against influenza A(H3N2) infection in ferrets compared to single vaccination - Ian York (CDC,USA)

Abstract No 10591: MHC class II proteins mediate cross-species entry of bat influenza viruses - Thiprampai Thamamongood (University of Freiburg, Germany)  

12:30 - 14:00

12:30 - 14:00

Lunch Break in Exhibit Hall

Sponsored Lunch Symposium - GSK

Prevention of paediatric Influenza: why and how?

14:00 - 15:30


Viral Replication Policy Perspectives for Pandemic Influenza Preparedness & Response Controlled Human Infection Model (CHIM) Challenge Studies

1 How Antiviral Proteins Can Stimulate Influenza Virus Replication-  Andrew Mehle (University of Wisconsin, USA)

1 Non-Pharmaceutical Public Health Measures for Mitigating the Risk and Impact of Epidemic and Pandemic Influenza - Ben Cowling (University of Hong Kong)

1: Insight into Host-pathogen Interactions in the Upper Respiratory Tract from Live-attenuated Influenza Vaccine Studies in Children- Thushan de Silva (The Gambia)

2 Visualizing Influenza Virus Assembly - Seema Lakdawala (University of Pittsburgh, USA) 2 Policy Considerations for Pandemic Preparedness and Response Planning - Vernon Lee (MOH, Singapore) 2: Mucosal Immunity in Pathogenesis and Protection Against Human Influenza Infection Challenge -  Chris Chiu (Imperial College London, UK)
3 Mini Viral RNAs: Consequences of RNA Structure for Genome Replication and Innate Immune Sensing -  David Bauer (University of Oxford, UK) 3 Policy considerations for pandemic preparedness and response planning -  Thailand's Experiences - Supamit Chunsuttiowat (Ministry of Public Health, Thailand) 3: Harnessing the Host Response to Generate Biomarkers for Influenza and other Respiratory Tract - Chris Woods (Duke University,USA)

Abstract No 10606: New genomic approaches to understand the heterogeneity of viral replication in single cells - David Bacsik (Fred Hutchinson Cancer Research Center, USA)

Panel Discussion: Overcoming Challenges for Pandemic Preparedness Planning -

Supamit Chunsuttiwat (Ministry of Public Health, Republic of Korea)

Seng Heng (Ministry of Health, Cambodia)

Chong Chee Kheong (Ministry of Health, Malaysia)

Abstract No 11082: Correlates of protection for better, faster influenza vaccine development  - Armen Donabedian (US Health and Human Services, USA)

Abstract No 10843: ANP32 proteins from different mammalian species act as host range barriers and shape influenza polymerase adaptation. - Thomas Peacock (Imperial College London, UK)

Abstract No 10943: Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human Influenza challenge model  - Delphine Guyon-Gellin (Osivax, France)  and Nicolas Noulin (hVIVO, UK)

15:30 - 16:00 Coffee Break in the Exhibit Hall
16:00 - 17:30


Influenza Evolution & Human Ecology Critical Influenza Illness Disease burden, Impact and Severity

1 Mapping Selection on Influenza Virus From Polyclonal Human Serum - Jesse Bloom (Fred Hutchinson Cancer Research Center, USA)

1 REMAP-CAP: A Platform Trial to Advance Knowledge of Optimal Treatment for Critically Ill Patients with Influenza - Steve Webb (Royal Perth Hospital, Australia)

1 Influenza Burden and Links to Policy - Building the Pyramid  Cheryl Cohen (National Institute for Communicable Diseases, South Africa)

2 Influenza in the Age of Mammals - Martha Nelson (National Institutes of Health, USA) 2 Neurological Complications Associated with Influenza - Tim Uyeki (CDC, USA) 2.Global Estimates of Influenza-Associated Hospitalization from the InfluEnza BurdEn, Global Project (IcEBErG) - Danielle Iuliano (CDC, USA)
3 Evolution of Seasonal Influenza Viruses - Colin Russell (University of Amsterdam, NL) 3 Cardiovascular Complications - William Fischer (University of North Carolina, USA)  

Abstract No 10822: The evolutionary dynamics of influenza A and influenza B viruses in naturally infected human hosts - Adam Lauring [University of Michigan, USA]

Abstract No 11151: Potential therapeutic role of bone marrow-derived mesenchymal stem cells in acute lung injury induced by highly pathogenic avian influenza virus A/H5N1 - Resti Yudhawati Meliana [ Airlangga University/Dr. Soetomo Hospital, Indonesia]

Abstract No 11044: The burden of in-hospital and out-of-hospital deaths among patients hospitalized with influenza, FluSurv-NET, 2010–2016 - Shikha Garg [CDC, USA

Abstract No 10995: ­­ Predicting evolutionary pathways to ‘fit’ oseltamivir resistant influenza viruses - Rubaiyea Farrukee [University of Melbourne, Australia] Abstract No 11309: Baloxavir for the treatment of Influenza virus infection in hematopoietic stem cell transplant recipients who failed oseltamivir - Mirella Salvatore [Weill Cornell Medicine, USA] Abstract No 10858: Estimating the number of deaths due to Influenza — An alternative to regression-based estimates of excess influenza mortality - Melissa Rolfes [ CDC, USA]
    Abstract No 10667: Community burden of influenza in a rural and an urban setting, south AFRICA, 2016-2017community burden of influenza in a rural and an urban setting, South Africa, 2016-2017 - Cheryl Cohen  [NICD, South Africa]
    Abstract No 10362: Under-detection of laboratory-Confirmed influenza-Associated hospitalizations among infants in a multi-country prospective study - Mark Thompson [CDC, USA]

17:30 - 19:00

Poster Session 3 - Public Health (Exhibit Hall)

19:30 Conference Gala Dinner at the Flower Dome - Gardens by the Bay (ticketed event)

Sunday, 1 September 2019

8:30 - 10:30


Non-Human Influenza Viruses Non-Pharmaceutical Interventions Imprinting, Sero-epidemiology, Age Profile Differences

1 Ten Years After the 2009 'Swine Flu' pandemic: A Perspective from a Veterinary Biomedical Researcherv- Kristien van Reeth (Ghent University, Belgium)

1 Contagious Phenotypes of Influenza Virus Infection - Donald Milton (University of Maryland School of Public Health, USA)

1 Epidemiological Consequences of Immune Memory - Sarah Cobey (University of Chicago, USA)

2 The Emergence, Epidemiology and Evolution of the H3N8 and H3N2 Canine Influenza Virus- Colin Parrish (Cornell University College of Veterinary Medicine, USA) 2 Spread of Pandemic Influenza in US Communities in 1920 and 2009: What Changed in the Last Century? Simon Cauchemez (Institut Pasteur, France)

2 Influenza in Context: Insights Into Universal Vaccination Against Influenza - Patrick Wilson (University of Chicago, USA)

3 Repeated Outbreaks of H5 Highly Pathogenic Avian Influenza in Wild Birds and Poultry in Europe  between 2014 and 2019 - Thijs Kulken (Erasmus University Medical Centre, NL)

Abstract No 10812: Reduced susceptibility viruses to baloxavir marboxil: Prognosis factors of the emergence and impact on clinical and virologic outcomes in pediatric patients in Japan – Takeki Uehara [Shionogi & Co., Ltd., Japan]

3 Using Serological Data to Reconstruct Historical Influenza Dynamics - Adam Kucharski (London School of Hygiene and Tropical Medicine, UK)

Abstract No 11198: Improving avian influenza surveillance through wetland sampling- Lauren Tindale [University of British Columbia, Canada]


Abstract No 11088: Effect of maternal pandemic vaccination on seroprevalence against influenza in children at birth and at 4 years - Anna Hayman Robertson [Norwegian Institute of Public Health, Norway]

Abstract No 11253: Repeated crow (corvus spendens) mortality events linked to H5N1 influenza virus circulation in live bird markets, Bangladesh - Ariful Islam [EcoHealth Alliance, USA]   Abstract No 11349: Risk factors and attack rates of seasonal influenza infection: Results of the SHIVERS Seroepidemiologic cohort study – Sue Huang [Institute of Environmental Science and Research, NZ]
  Abstract No 10910: Quantifying the effects of school closures on mitigation of influenza epidemics in Hong Kong - Sheikh Taslim Ali [The University of Hong Kong, Hong Kong] Abstract No 11206: Serosolver: An open source tool to infer epidemiological and immunological dynamics from serological data - Steven Riley [Imperial College, UK]
  Abstract No 10466: Access to telework, paid leave benefits and work attendance in adults with medically-attended acute respiratory illness (ARI) - Faruque Ahmed [CDC, USA] Abstract No 11162: Antibody response and influenza-like illness among healthcare workers after influenza vaccination - Vivian Leung [Peter Doherty Institute for Infection and Immunity, Australia]
    Abstract No 11051: Hemagglutinin and neuraminidase antibodies are induced in an age- and subtype- dependent manner after influenza virus infection. - Sook-San Wong [Guangzhou Medical University, People’s Republic of China]
10:30 - 11:00

Coffee Break in Exhibit Hall

11:00 - 13:00


Emerging Influenza Viruses Vaccines Epidemiology and Transmission Dynamics

1 Fighting Influenza from a One Health Perspective - Ab Osterhaus (TiHO, Germany)

1 Influenza Vaccination of the Immunocompromised - Deepali Kumar (University Health Network, Can)

1 Healthcare Outbreaks of Influenza - Paul Tambyah (National University of Singapore, SG)

2 Emergence of swine influenza in Australia - Vijay Dhanasekaran (Monash University, Australia) 2 On Waning and Boosting: Is There a Sweet Spot for Influenza Vaccination Strategies in the Tropics?  Barnaby Young (National Centre for Infectious Diseases, SG) 2 Deep Sequencing and Mapping Chains of Transmission - Sebastian Maurer Stroh (A*STAR, SG)
3 Emergence of Avian Influenza Viruses in Asia - Maria Zhu (The University of Hong Kong)

Abstract No 10324: Vaccine induced mucosal IgA contributes to protection against influenza infection in humans -  Sean Tucker [Vaxart, Inc., USA]      



Abstract No 10448: Preliminary estimates of the incidence of influenza-associated acute respiratory infection among adults aged  >60 years in a multi-site community cohort in India – Rakesh Kumar [All India Institute of Medical Sciences, India]

4 Reverse Genetic Analysis of Bat Influenza Viruses: A Journey Full of Surprises - Martin Schwemmle (University of Freiburg, Germany) Abstract No 11083: Towards an improved wild-type sequence based hemagglutination inhibition assay for the evaluation of influenza vaccines: challenges and new developments.  -  Vivek Shinde [Novavax, USA]  Abstract No 10352: Influenza virus transmission from symptomatic and asymptomatic individuals in a rural and an urban setting, South Africa, 2016-2017 - Meredith McMorrow [CDC, South Africa]

Abstract No 11179: Few substitutions of H5 gene belonging to Clade 2.3.4 have altered the NA gene preferences of the virus other than N1 – Khristine Joy Antigua [Chungbuk National University, South Korea]

Abstract No 10944: First-in-man clinical trials of  influenza vectored vaccines against tuberculosis with intranasal and sublinqual routes of administration - Marina Stukova [Smorodintsev Research Institute of Influenza, Russian Federation] Abstract No 10702: Impact of influenza antigenic evolution on disease dynamics in the United States - Amanda Perofsky [Fogarty International Center, National Institutes of Health, USA]
Abstract No 10649: Comprehensive mapping of adaptation of the avian influenza polymerase protein PB2 to humans - Shirleen Soh [Fred Hutchinson Cancer Research Center, USA] Abstract No 10937: OVX836, A novel universal influenza A vaccine candidate: First results of a phase I clinical trial in humans - Alexandre Le Vert [Osivax, France] 

Abstract No 10492: Determinants of influenza transmission in households in rural North India – Aslesh Ottapura Prabhakaran [US CDC India Office, India]

Abstract No 10960: Mitigating pandemic risk with influenza a virus field surveillance: Mia (Mobile Influenza Analysis) - John R. Barnes [CDC, USA] Abstract No 11095: Immune history to influenza is a novel correlate of protection of influenza vaccination -  Tomer Hertz [ Ben-Gurion University of the Negev ] Abstract No 11200: Effect of host genetic polymorphism on transmission of influenza virus infection in a household setting - Dennis Kai Ming Ip [The University of Hong Kong, Hong Kong]
  Abstract No 11073: Induction of broadly cross-reactive immune responses against A(H3N2) viruses: results of a phase 2 trial of a novel recombinant hemagglutinin saponin-adjuvanted nanoparticle influenza vaccine - Vivek Shinde  [Novavax, USA] 

Abstract No 11001: The Epidemioloogical Signature of the influenza B/Victoria and B/Yamagata Lineages in the 21st Century – John Paget [Nivel, Netherlands]

13:00-13:30 Refreshment Break
13:30 - 15:00

Closing Plenary Session

Mitigating Against Geopolitical Determinants of Global Public Health and Envisioning Counterfactual Futures for Outbreak Preparedness and Response - Gabriel Leung (University of Hong Kong)

The Future of Influenza Vaccines - Arnold Monto (University of Michigan School of Public Health, USA)

Future Response & WHO Initiatives - Sylvie Brand (WHO, Switzerland)